Niclosamide Role in Diabetic Nephropathy

Status Completed

Clinical Trial Summary

This study is randomized, controlled, parallel, prospective clinical study will be conducted on 60 patients diagnosed with type 2 diabetes mellitus at least five years ago. Patients will be recruited from Tanta University Hospital, Tanta, Egypt. Accepted patients will be randomized into 2 groups as the following: Control group: 30 patients will receive maximum tolerated dose of ACEI plus placebo pills for six months Treatment group: 30 patients will receive maximum tolerated dose of ACEI plus niclosamide tablets 1 gram once daily for six months The primary end point will be the change in Urinary albumin to creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) after six months of treatment

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04317430
Study type	Interventional
Source	Tanta University
Contact
Status	Completed
Phase	Phase 3
Start date	February 1, 2020
Completion date	April 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05530356` - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Terminated	`NCT01575379` - A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes	Phase 4
Active, not recruiting	`NCT05656963` - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Not yet recruiting	`NCT04084886` - TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy
Active, not recruiting	`NCT04869761` - Stem Cell Therapy for Chronic Kidney Disease	Phase 1
Recruiting	`NCT04570735` - MRI Biomarkers in Diabetic Kidney Disease
Completed	`NCT03165240` - This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated	Phase 1
Completed	`NCT01968668` - Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)	Phase 2
Completed	`NCT02552277` - A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy	Phase 2
Terminated	`NCT03840343` - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Phase 1
Terminated	`NCT02410005` - Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)	Phase 2/Phase 3
Unknown status	`NCT01918488` - Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease	N/A
Completed	`NCT00915200` - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy	Phase 2
Completed	`NCT03165227` - This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)	Phase 1
Active, not recruiting	`NCT04531163` - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy	Phase 2/Phase 3
Active, not recruiting	`NCT03620773` - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes	Phase 1/Phase 2
Completed	`NCT03618420` - Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function	Phase 1/Phase 2
Not yet recruiting	`NCT03284996` - Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus.	N/A
Completed	`NCT03334318` - PERL Continuous Glucose Monitoring (CGM) Study
Completed	`NCT04380584` - Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.